Novartis
NEWS
A post-hoc analysis of a Phase II sickle cell disease study showed that patients treated with crizanlizumab significantly reduced occurrences of vaso-occlusive crisis, a serious disease complication that can lead to organ failure.
Genentech, a Roche company, released data from a long-term clinical trial of Ocrevus in multiple sclerosis. Meanwhile, Novartis isn’t standing still on MS. Earlier this week the company announced that both the FDA and EMA had accepted its NDA and MAA, respectively, for siponimod.
The AP in a recent report notes that drug price increases “slowed somewhat and were not quite as steep as in past years.” But overall, there has been no “massive” drug price cuts.
To spur innovation and bolster ties with tech giants, Swiss pharma giant Novartis plans to set up innovation labs across the globe to partner with these companies to spur the development of new therapies.
Bristol-Myers Squibb, Nektar Therapeutics, Amgen and others will be recognized for their significant contributions to the California life sciences industry during the November 2018 Pantheon DiNA Awards hosted by the California Life Sciences Association.
A study published in the Annals of Internal Medicine highlights some of the problems that drug shortages bring to the healthcare system, including a rise in prices. The research, as highlighted by Business Insider, examined the prices of 917 drugs that were in shortage between 2015 and 2016.
Swiss pharma giant Novartis could be on its way to securing regulatory approval for its secondary progressive multiple sclerosis (SPMS) treatment siponimod.
The use of multiple, potentially costly, drugs during combination therapy all contributes to the high costs in oncology. DO you know why does immunotherapy cost so much?
Boston Pharma went on a buying binge, licensing a slew of compounds from GlaxoSmithKline and Novartis in two separate deals.
JOBS
IN THE PRESS